Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

Table 6 shows relevant metrics prostate and organs at risk for prescription doses of 35 Gy to the prostate and 42 Gy to the intraprostatic tumor mass in 5 fractions. Median and interquartile ranges are shown

	Prostate volume	Boost volume (absolut / % of prostate volume)	PTV prostate	PTV boost volume		Bladder		Rectum			Urethra
Prescition dose (Prostate/Boost)			D98%	D50%	D98%	D0.03cc	D15%	D0.03cc	D2cc	D20%	D0.01cc	D50%
35/42 Gy	34.5 (29.3–42-5)	13.2 (8.3–21.1) / 32 (28–55)	33.8 (33.4–33.9)	42.4 (42–42.5)	39.3 (38.3–39.9)	36.1 (35.1–36.6)	20.2 (17.3–22.2)	37.1 (36.4–37.8)	34.8 (32.7–34.8)	18.9 (16.0–21.0)	39.8 (39.5–40.2)	35.7 (35.7–36.4)

ISSN: 1471-2407